{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:30:00Z","timestamp":1790667000118,"version":"4.1.0"},"reference-count":22,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010090","name":"Women and Children\u2019s Health Research Institute","doi-asserted-by":"publisher","award":["$2,000.00 as operating\/publication funds, and $780"],"award-info":[{"award-number":["$2,000.00 as operating\/publication funds, and $780"]}],"id":[{"id":"10.13039\/100010090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Can J Kidney Health Dis"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>There is known practice variation in the treatment of frequently relapsing, steroid-dependent, and steroid-resistant nephrotic syndrome in children. Rituximab is an emerging therapy for difficult-to-treat nephrotic syndrome; however, there are no clear treatment guidelines. We therefore hypothesized that a wide variety of approaches to this therapy exist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate when and how rituximab is used for the treatment of childhood nephrotic syndrome in Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and setting:<\/jats:title>\n                    <jats:p>An online survey was used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants:<\/jats:title>\n                    <jats:p>Canadian pediatric nephrologists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A cross-sectional survey was distributed across Canada through the Canadian Association of Pediatric Nephrologists (CAPN) to evaluate rituximab treatment practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of a total of 20 responses, 19 (95%) use rituximab in the treatment of nephrotic syndrome, usually as a third or fourth agent. For the number of rituximab doses, the majority (68%) uses 2 doses each time they use it. Eighteen respondents (90%) measure B cells when using this medication, mostly monthly (50%) or every 3 months (39%). Respondents administered additional doses of rituximab prophylactically (74%) or at first relapse (47%). Long-term drug safety and drug funding were identified as the main barriers to rituximab use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations:<\/jats:title>\n                    <jats:p>This survey represents the practice styles of physicians in a single country, and there is a nonresponse bias of 63%. Also, associations were not calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Among Canadian pediatric nephrologists, rituximab use for nephrotic syndrome appears to be increasing, but significant practice variations remain, including approaches to B-cell monitoring. It is reserved mostly for second-line and third-line use due to cost, funding issues, and residual uncertainty regarding long-term safety. Understanding these critical areas of practice uncertainty is a first step to optimize treatment of nephrotic syndrome in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20543581221079959","type":"journal-article","created":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T01:22:01Z","timestamp":1647048121000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Rituximab Use for the Treatment of Childhood Nephrotic Syndrome by Canadian Pediatric Nephrologists: A National Survey"],"prefix":"10.1177","volume":"9","author":[{"given":"Cory","family":"Meeuwisse","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Samuel","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-7894","authenticated-orcid":false,"given":"R Todd","family":"Alexander","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-4855","authenticated-orcid":false,"given":"Sara","family":"Rodriguez-Lopez","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"bibr1-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3677-5"},{"key":"bibr2-20543581221079959","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"bibr3-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-013-2546-0"},{"key":"bibr4-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012704"},{"key":"bibr5-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.01.008"},{"key":"bibr6-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-016-0271-6"},{"key":"bibr7-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014080799"},{"key":"bibr8-20543581221079959","doi-asserted-by":"publisher","DOI":"10.3892\/br.2016.711"},{"key":"bibr9-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1007\/s40124-014-0065-5"},{"key":"bibr10-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-015-3197-0"},{"key":"bibr11-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002231"},{"key":"bibr12-20543581221079959","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09421010"},{"key":"bibr13-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296"},{"issue":"1","key":"bibr14-20543581221079959","first-page":"27","volume":"12","author":"Hoseini R","year":"2018","journal-title":"Iran J Kidney Dis"},{"key":"bibr15-20543581221079959","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03470410"},{"key":"bibr16-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.211"},{"key":"bibr17-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60541-9"},{"key":"bibr18-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013030251"},{"key":"bibr19-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011080775"},{"key":"bibr20-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.09.033"},{"key":"bibr21-20543581221079959","doi-asserted-by":"publisher","DOI":"10.23876\/j.krcp.2017.36.3.257"},{"key":"bibr22-20543581221079959","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12744"}],"container-title":["Canadian Journal of Kidney Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20543581221079959","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20543581221079959","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20543581221079959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:24:11Z","timestamp":1777389851000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20543581221079959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":22,"alternative-id":["10.1177\/20543581221079959"],"URL":"https:\/\/doi.org\/10.1177\/20543581221079959","relation":{},"ISSN":["2054-3581","2054-3581"],"issn-type":[{"value":"2054-3581","type":"print"},{"value":"2054-3581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"20543581221079959"}}